Equity Insider News Commentary
Issued on behalf of Avant Technologies Inc.
VANCOUVER, BC, May 16, 2025
/PRNewswire/ -- Equity Insider News Commentary –
AI is no longer just assisting healthcare — it's beginning to
rewire it from the ground up. From streamlining diagnostics and
automating clinical documentation to predicting disease and
optimizing hospital operations, generative AI is now touching every
layer of the care continuum. As policymakers in places like
Connecticut debate how to regulate
this growing influence, and initiatives like OpenAI's
HealthBench push the frontier of model evaluation, a new
class of enterprise-scale innovators is already moving ahead. Among
them are several public companies straddling health tech, cloud AI,
and data infrastructure — including Avant Technologies, Inc.
(OTCQB: AVAI), Palantir Technologies Inc. (NASDAQ: PLTR),
GE HealthCare Technologies Inc. (NASDAQ: GEHC),
Salesforce, Inc. (NYSE: CRM), and Alphabet Inc.
(NASDAQ: GOOG, GOOGL).
Industry analysts at MarketsandMarkets project that the
AI in healthcare market will expand at a compound annual growth
rate of 38.6%, reaching over $110
billion by 2030. Looking further ahead, Accenture
estimates that AI could unlock an additional $461 billion in value by 2035—augmenting a global
healthcare sector already expected to exceed $2.26 trillion.
Avant Technologies, Inc. (OTCQB: AVAI) is quietly but
deliberately advancing its position in AI-powered healthcare
through a proposed acquisition of its joint venture partner,
Ainnova Tech. The two companies, already aligned under the
Ai-nova Acquisition Corp. (AAC) banner, are now moving to
unify operations—an intentional step that comes just ahead of their
scheduled FDA pre-submission meeting this July. If
completed, the merger would remove internal friction, streamline
clinical trial planning, and strengthen their regulatory posture
ahead of potential U.S. market entry.
"We believe bringing the two companies together will offer
tremendous value for shareholders," said Vinicio Vargas, CEO at Ainnova and a
member of the Board of Directors of Ai-nova Acquisition
Corp. "It will simplify the process of advancing our technology
to market, and it will deliver value to our customers and partners
as we promote our technology portfolio globally."
At the core of this effort is Vision AI, a non-invasive clinical
screening platform that combines retinal imaging, vital sign
capture, and machine-learning algorithms to detect early signals of
chronic illness—including diabetic retinopathy, cardiovascular
disease, kidney and liver conditions, and type 2 diabetes.
Operating under AAC, the joint venture holds global rights
to the platform, which has shown more than 90% sensitivity in early
detection, according to NIH-cited research.
"This milestone reflects our two-tiered strategy, rapid
deployment in low-regulation markets where Vision AI operates as a
screening tool, and simultaneous progress toward FDA
clearance for the U.S. market," said Vargas. "Entering the U.S.
will unlock significant commercial potential, and early engagement
with regulators ensures we do so with speed, credibility, and a
validated product."
Unlike many healthcare AI startups still stuck at concept stage,
Avant's technology is already deployed in Latin America—including Chile, Mexico, and Brazil—where it's being tested in real-world
clinical workflows. These field programs are not only helping build
a safety and efficacy track record, they're also providing critical
user feedback that shapes the platform's refinement and
usability.
To support broader clinical reach, AAC recently
integrated four new diagnostic algorithms into Vision AI. Trained
on over 2.3 million clinical cases, these additions enhance the
system's utility across a wider range of chronic conditions. With
proven traction abroad and a pending regulatory milestone in the
U.S., Avant is moving from potential to presence—and may soon find
itself on the radar of a much larger healthcare conversation.
CONTINUED... Read this and more news for Avant
Technologies at:
https://equity-insider.com/2025/03/21/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/
Palantir Technologies Inc. (NASDAQ: PLTR) has
entered a long-term partnership with The Joint Commission,
the leading healthcare accreditation body in the U.S., to apply its
AI and data analytics platform to improve patient safety and
operational efficiency.
"The Joint Commission is committed to building the
accreditation and certification process of the future, today," says
Alex Karp, co-founder and CEO of
Palantir Technologies. "This work will improve global health
outcomes by utilizing AI to drive performance improvements around
the world."
The collaboration aims to modernize how hospitals manage quality
standards, streamline certification processes, and enhance clinical
performance. Palantir's platform is already delivering
results across major healthcare systems, including Tampa
General and Cleveland Clinic.
GE HealthCare Technologies Inc. (NASDAQ:
GEHC) recently unveiled CleaRecon DL, an
FDA-cleared, AI-based solution aimed at elevating image
quality in cone-beam CT (CBCT) procedures. Powered by deep
learning, the tool addresses long-standing image distortion
challenges caused by blood flow and contrast variability,
especially in interventional settings like liver and neuro
procedures. Clinical validation shows a 94% increase in
interpretation confidence and a 98% improvement in image clarity
compared to traditional CBCT.
"The introduction of CleaRecon DL represents a leap forward in
the interventional suite and for the advancement of CBCT," said
Arnaud Marie, General Manager,
Interventional Solutions at GE HealthCare. "By improving
image quality and reducing artifacts, this technology can empower
clinicians to perform procedures with greater precision and
confidence. This solution builds on our portfolio of tools aimed at
improving the user experience and workflow efficiency, enabling
clinicians to deliver more accurate and effective interventions for
enhanced patient outcomes."
Salesforce, Inc. (NYSE: CRM) is expanding its
healthcare footprint with the launch of a global Life Sciences
Partner Network and broader deployment of its Agentforce digital
labor platform. Designed to unify clinical, commercial, and
manufacturing data, the initiative enables pharmaceutical and
medtech organizations to transition from legacy systems to
AI-enabled, compliant workflows.
"We are in an unprecedented market moment where, with digital
labor grounded in rich data, international life sciences
organizations have the opportunity to completely reimagine the way
they interact with patients and HCPs," said Frank Defesche, Senior Vice President and
General Manager, Salesforce Life Sciences. "Backed by over
two decades of industry expertise, Salesforce is uniquely equipped
to pioneer this next era with our deeply unified Platform that
brings together apps, data, life sciences-specific workflows, and
AI – all wrapped in trust and compliance."
With integrations from partners like athenahealth,
Viz.ai, and H1, the platform supports real-time
insights, patient engagement, and automated compliance across the
healthcare lifecycle. This marks a major step in
Salesforce's push to become the digital backbone of modern
life sciences operations.
Alphabet Inc. (NASDAQ: GOOG, GOOGL), through Google
Cloud and Google Public Sector, has partnered with
Drive Health and the State of
Illinois to launch Healthy Baby, a multi-year AI-powered
maternal health pilot targeting underserved communities. The
program equips expectant mothers with Google Pixel phones
and Fitbit devices, delivering personalized care through Nurse
Avery, an AI health assistant.
"The Healthy Baby pilot represents a critical step in maternal
healthcare, showing how AI can help deliver personalized, proactive
health support directly to underserved mothers," said Chris Hein, Field Chief Technology Officer,
Google Public Sector. "Using the AI agent, Nurse Avery, and
delivering it through Google Pixel phones and Fitbit devices, the
program provides real-time support – managing appointments,
monitoring vitals, and offering health guidance directly, aiming to
make essential resources more readily available."
Backed by Google Cloud's secure infrastructure, the
initiative aims to reduce maternal mortality, improve birth
outcomes, and close care gaps across rural populations.
Source:
https://equity-insider.com/2025/03/21/unlocking-the-trillion-dollar-ai-market-what-investors-
need-to-know/
CONTACT:
Equity
Insider
info@equity-insider.com
(604)
265-2873
DISCLAIMER: Nothing in this publication should be
considered as personalized financial advice. We are not licensed
under securities laws to address your particular financial
situation. No communication by our employees to you should be
deemed as personalized financial advice. Please consult a licensed
financial advisor before making any investment decision. This is a
paid advertisement and is neither an offer nor recommendation to
buy or sell any security. We hold no investment licenses and are
thus neither licensed nor qualified to provide investment advice.
The content in this report or email is not provided to any
individual with a view toward their individual circumstances.
Equity Insider is a wholly-owned subsidiary of Market IQ Media
Group, Inc. ("MIQ"). MIQ has been paid a fee for Avant Technologies
Inc. advertising and digital media from the company directly. There
may be 3rd parties who may have shares Avant Technologies Inc., and
may liquidate their shares which could have a negative effect on
the price of the stock. This compensation constitutes a conflict of
interest as to our ability to remain objective in our communication
regarding the profiled company. Because of this conflict,
individuals are strongly encouraged to not use this publication as
the basis for any investment decision. The owner/operator of MIQ
own shares of Avant Technologies Inc. which were purchased in the
open market. MIQ reserves the right to buy and sell, and will buy
and sell shares of Avant Technologies Inc. at any time thereafter
without any further notice. We also expect further compensation as
an ongoing digital media effort to increase visibility for the
company, no further notice will be given, but let this disclaimer
serve as notice that all material disseminated by MIQ has been
approved by the above mentioned company; this is a paid
advertisement, and we own shares of the mentioned company that we
will sell, and we also reserve the right to buy shares of the
company in the open market, or through other investment vehicles.
While all information is believed to be reliable, it is not
guaranteed by us to be accurate. Individuals should assume that all
information contained in our newsletter is not trustworthy unless
verified by their own independent research. Also, because events
and circumstances frequently do not occur as expected, there will
likely be differences between any predictions and actual results.
Always consult a licensed investment professional before making any
investment decision. Be extremely careful, investing in securities
carries a high degree of risk; you may likely lose some or all of
the investment.
Logo -
https://mma.prnewswire.com/media/2644233/5323825/Equity_Insider_Logo.jpg
View original content to download
multimedia:https://www.prnewswire.com/news-releases/new-healthcare-ai-models-could-reshape-everything-from-burnout-to-diagnostics-302458034.html
SOURCE Equity Insider
